"The
Report Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte
Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2016
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Global
Markets Directs, Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or
Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2
2016, provides in depth analysis on Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
targeted pipeline therapeutics.
The
report provides comprehensive information on the Tyrosine Protein
Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC
2.7.10.2), targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved
in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus
Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development and
features dormant and discontinued projects.
View Report At
http://www.marketresearchreports.biz/analysis/794365
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/794365
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus
Kinase or JAK3 or EC 2.7.10.2)
-
The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or
Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
under development by companies and universities/research institutes
based on information derived from company and industry-specific
sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Tyrosine Protein Kinase
JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC
2.7.10.2) targeted therapeutics and enlists all their major and minor
projects
-
The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or
Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
based on mechanism of action (MoA), route of administration (RoA) and
molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Tyrosine Protein
Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC
2.7.10.2) targeted therapeutics
Reasons to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus
Kinase or JAK3 or EC 2.7.10.2)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus
Kinase or JAK3 or EC 2.7.10.2) development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report
Coverage 8
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
Overview 9
Therapeutics Development 10
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Products under Development by Stage of Development 10
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Products under Development by Therapy Area 11
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Products under Development by Indication 12
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Products under Development by Companies 16
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Therapeutics Assessment 20
Assessment by
Monotherapy/Combination Products 20
Assessment by Mechanism of Action
21
Assessment by Route of
Administration 22
Assessment by Molecule Type 24
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Companies Involved in Therapeutics Development 25
Aclaris Therapeutics, Inc. 25
Advinus Therapeutics Ltd 26
Arrien Pharmaceuticals, LLC 27
Astellas Pharma Inc. 28
Bristol-Myers Squibb Company 29
Chipscreen Biosciences Ltd 30
Creabilis SA 31
F. Hoffmann-La Roche Ltd. 32
Ligand Pharmaceuticals, Inc. 33
MYOS RENS Technology Inc. 34
Pfizer Inc. 35
Portola Pharmaceuticals, Inc. 36
Principia Biopharma Inc. 37
Rigel Pharmaceuticals, Inc. 38
Theravance Biopharma, Inc. 39
Vectura Group Plc 40
Tyrosine Protein Kinase JAK3
(Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) -
Drug Profiles 41
ARN-4079 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ATI-50001 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ATI-50002 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment